Fast Like EpiPen: Mylan Reaches Quick Settlement Over Medicaid Rebates

$465m settlement with DOJ to resolve questions about EpiPen's classification is roughly the size of autoinjector's Medicaid and Medicare sales last year; Mylan expects to enter corporate integrity agreement.

EpiPen

Mylan NV did not wait for the Department of Justice to carry out an investigation of its Medicaid charges for EpiPen (epinephrine). Soon after being questioned about Medicaid rebates for the emergency allergy treatment, the company announced it had reached a $465m settlement with the government.

In an Oct. 7 release, Mylan said it had agreed to the terms of a settlement with the DOJ and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Compliance

More from Pink Sheet